Bex A - Search Results

1

Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities.

Bex A, Larkin J, Blank C. Bex A, et al. Curr Oncol Rep. 2011 Jun;13(3):240-8. doi: 10.1007/s11912-011-0159-y. Curr Oncol Rep. 2011. PMID: 21298371 Review.

2

The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.

Bex A, Horenblas S, de Gast GC. Bex A, et al. Technol Cancer Res Treat. 2003 Jun;2(3):205-10. doi: 10.1177/153303460300200304. Technol Cancer Res Treat. 2003. PMID: 12779351 Free article. Review.

3

A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor.

Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, de Gast GC. Bex A, et al. Cancer Immunol Immunother. 2005 Jul;54(7):713-9. doi: 10.1007/s00262-004-0630-9. Epub 2004 Dec 31. Cancer Immunol Immunother. 2005. PMID: 15627213 Free PMC article. Clinical Trial.

4

Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.

Bex A, Kerst M, Mallo H, Meinhardt W, Horenblas S, de Gast GC. Bex A, et al. Eur Urol. 2006 Jan;49(1):76-81. doi: 10.1016/j.eururo.2005.09.011. Epub 2005 Nov 2. Eur Urol. 2006. PMID: 16310929 Clinical Trial.

5

Sunitinib for treatment of advanced renal cell cancer: primary tumor response.

van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Bex A, de Gast G, Haanen JB, Boven E. van der Veldt AA, et al. Among authors: bex a. Clin Cancer Res. 2008 Apr 15;14(8):2431-6. doi: 10.1158/1078-0432.CCR-07-4089. Clin Cancer Res. 2008. PMID: 18413834

6

Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.

Bex A, Haanen JB, Vyth-Dreese FA, Horenblas S, de Gast GC. Bex A, et al. Urol Int. 2008;80(4):367-71. doi: 10.1159/000132693. Epub 2008 Jun 27. Urol Int. 2008. PMID: 18587246

7

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery.

Bex A, van der Veldt AA, Blank C, van den Eertwegh AJ, Boven E, Horenblas S, Haanen J. Bex A, et al. World J Urol. 2009 Aug;27(4):533-9. doi: 10.1007/s00345-008-0368-7. Epub 2009 Jan 15. World J Urol. 2009. PMID: 19145434

8

Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.

Bex A, Van der Veldt AA, Blank C, Meijerink MR, Boven E, Haanen JB. Bex A, et al. Acta Oncol. 2010 May;49(4):520-3. doi: 10.3109/02841860903521111. Acta Oncol. 2010. PMID: 20105087 No abstract available.

9

Feasibility of sentinel node detection in renal cell carcinoma: a pilot study.

Bex A, Vermeeren L, de Windt G, Prevoo W, Horenblas S, Olmos RA. Bex A, et al. Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1117-23. doi: 10.1007/s00259-009-1359-7. Epub 2010 Jan 29. Eur J Nucl Med Mol Imaging. 2010. PMID: 20111964

10

Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.

Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T, van Poppel H, Wood CG. Bex A, et al. Eur Urol. 2010 Dec;58(6):819-28. doi: 10.1016/j.eururo.2010.08.029. Epub 2010 Aug 27. Eur Urol. 2010. PMID: 20828919 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

368 results

Search Page

Filters